MergerSep 17, 2026, 08:08 AM
Aethlon Medical Merges With North Immunology; $180M Private Placement
AI Summary
Aethlon Medical, Inc. (AEMD) announced a definitive merger agreement with North Immunology, Inc. in an all-stock transaction. The combined entity will operate as North Immunology, Inc. and trade on the Nasdaq Capital Market under the new ticker symbol NRTX. The merger is accompanied by an oversubscribed private placement expected to raise approximately $180 million, which is anticipated to fund the combined company's operations into the second half of 2028. North Immunology's lead program, NOR-101, a bispecific antibody for atopic dermatitis, is slated for a Phase 1a study initiation in Q1 2027. Aethlon stockholders will receive contingent value rights related to the legacy Hemopurifier® business.
Key Highlights
- Aethlon Medical and North Immunology to merge in an all-stock transaction.
- North Immunology's lead program NOR-101 is a bispecific antibody for atopic dermatitis.
- Combined company to operate as North Immunology, Inc. and trade under ticker NRTX.
- Oversubscribed private placement expected to provide $180 million in gross proceeds.
- Phase 1a study of NOR-101 expected to begin in Q1 2027.
- Pre-merger North Immunology stockholders expected to own ~95.25% of the combined company.
- Pre-merger Aethlon stockholders expected to own ~4.75% of the combined company.
- Contingent value right (CVR) for Aethlon stockholders related to legacy Hemopurifier® business.
Price Impact
More from AEMD